Jansen et al. revealed that inhibiting TLS pol Rev1 sensitized chronic myeloid leukemia (CML) cells to genotoxic chemotherapeutic agents, increasing DNA damage and downregulating stem cell-related genes [52]. Here, REV1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.